We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

INBIOS INTERNATIONAL

InBios International, Inc. is a biotechnology company specializing in the design, development and manufacture of immu... read more Featured Products: More products

Download Mobile App




Anti-Dengue Virus IgM Detected in Urine

By LabMedica International staff writers
Posted on 20 Feb 2020
Dengue viruses (DENV) are transmitted to humans by infected mosquitoes and the disease, known as dengue, occurs throughout the tropics and subtropics. More...
Dengue diagnostic tests rely on a blood sample taken within two weeks of illness onset.

Dengue initially presents as an acute febrile illness (AFI) that can be difficult to diagnose clinically and differentiate from other AFIs such as malaria, leptospirosis, influenza, and chikungunya; however, even if dengue is suspected and diagnosed early, a patient’s clinical course and outcome is unpredictable.

Scientists at the University of Puerto Rico (San Juan, Puerto Rico) and their colleagues used specimens collected from 1,538 study participants enrolled between May 2012-March 2013, of an AFI study conducted in Ponce, Puerto Rico. Study participants with fever for ≤7 days were enrolled, a medical history was obtained, and serum and urine specimens were collected.

Serum specimens collected ≤6 days post-illness onset (DPO) were tested by real-time reverse transcription polymerase chain reaction (rRT-PCR ) to detect DENV nucleic acid as previously described. Serum specimens collected ≥4 DPO were tested for the presence of anti-DENV IgM by DENV Detect IgM ELISA (InBios International, Inc., Seattle, WA, USA). Urine was tested for anti-DENV IgM, and its sensitivity and specificity to detect sera laboratory-positive dengue cases were calculated. The team evaluated if urine anti-DENV IgM positivity early (≤5 days DPO) and late (6–14 DPO) in the clinical course was associated with dengue severity.

The scientists reported that urine anti-DENV IgM sensitivity and specificity were 47.4% and 98.5%, respectively, when compared with serum anti-DENV IgM ELISA results, and 29.7% and 91.1% when compared with serum rRT-PCR results. There was no correlation between urine anti-DENV IgM positivity and patient sex or pre-existing chronic disease. Early in the clinical course, a significantly higher proportion of those who developed dengue with warning signs had anti-DENV IgM in their urine when compared to those without warning signs (20.4% versus 4.3%). There was no difference in the proportion with urine anti-DENV IgM positivity between severity groups late in the clinical course.

The authors concluded that the use of urine as a surrogate specimen for dengue diagnosis was not sensitive in comparison to serum; however, the presence of anti-DENV IgM urine was highly specific. They were able to identify the presence of anti-DENV IgM in urine specimens from laboratory-positive dengue cases using a simple diagnostic assay. This assay may prove to be useful as a diagnostic tool as well as a prognostic tool to differentiate dengue from dengue with warning signs early in the course of illness (DPO<5). The study was published on January 29, 2020 in the journal PLOS Neglected Tropical Diseases.

Related Links:
University of Puerto Rico
InBios International



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.